By Budi Oetomo Narendra 
For some of the most aggressive blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a stem cell transplant may represent the only treatment offering a potential cure. However, the daunting reality is that even after successful transplantation, these relentless cancers frequently return, leaving clinicians with severely limited therapeutic options. A groundbreaking new clinical trial, spearheaded by researchers at Washington University School of Medicine in St. Louis, has unveiled a revolutionary strategy that could fundamentally alter this landscape: genetically modifying donor stem cells prior to transplantation to render subsequent cancer treatments both safer and potentially more potent. This innovative approach involves precisely removing a specific protein from donor cells, thereby creating a biological "shield" that allows targeted therapies to attack malignant cells without harming the healthy, newly engrafted blood-forming cells.
The pivotal study, a multi-center effort conducted at the renowned Siteman Cancer Center – based at Barnes-Jewish Hospital and WashU Medicine – alongside 14 other leading medical institutions across the United States and Canada, has yielded promising results. These findings, which mark a significant leap forward in cancer treatment, were recently published in the esteemed journal Nature Medicine, drawing considerable attention from the global oncology community.
The Unmet Need: Addressing Aggressive Blood Cancers and CAR-T Limitations
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are among the most challenging hematologic malignancies. AML is characterized by the rapid growth of abnormal myeloid cells in the bone marrow, interfering with the production of normal blood cells, while MDS involves ineffective production of blood cells, often progressing to AML. For many patients, especially those with high-risk genetic profiles or relapsed disease, allogeneic stem cell transplantation (where healthy stem cells from a donor replace the patient’s diseased bone marrow) offers the best chance for long-term survival. However, even with successful transplantation, relapse rates remain high, and options for treating recurrent disease are scarce and often associated with significant toxicity.
The advent of Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of certain B-cell lymphomas and leukemias, demonstrating unprecedented efficacy. Yet, its application against AML and MDS has been severely hampered by a critical biological challenge. As explained by Dr. John F. DiPersio, MD, PhD, the Virginia E. & Sam J. Golman Professor of Medicine at WashU Medicine and corresponding author of the Nature Medicine study, the gene editing approach detailed in their research holds the key to overcoming a major obstacle that has historically limited the utility of CAR-T cell therapy in these aggressive forms of blood cancer.
The core impediment lies in the unfortunate fact that many of the surface proteins targeted by CAR-T cells on AML and MDS cancer cells are also ubiquitously present on healthy myeloid cells, including the crucial donor stem cells utilized in transplantation procedures. For instance, CD33 is a protein commonly expressed on AML blast cells, making it an attractive therapeutic target. However, CD33 is also present on normal myeloid progenitor cells. If CAR-T cells are engineered to recognize and destroy one of these shared "antigens," they inevitably engage in a devastating "on-target, off-tumor" attack, indiscriminately annihilating healthy blood stem cells alongside the cancerous ones. This collateral damage is not merely an unfortunate side effect; it can trigger a dangerous and life-threatening inflammatory response known as cytokine release syndrome, severely compromise the patient’s ability to produce healthy blood cells (myelosuppression), and critically weaken the cancer treatment itself. When large numbers of precious CAR-T cells are diverted to attack healthy targets, their concentration and efficacy against the malignant cells are drastically diminished, rendering the therapy less effective or even futile.
The landscape for AML and MDS patients, especially those whose disease has relapsed after an initial stem cell transplant, has historically been bleak. Standard chemotherapy regimens often prove insufficient, and the inherent toxicities of existing therapies pose significant risks to already vulnerable patients. The inability to safely deploy highly potent immunotherapies like CAR-T cells against these cancers has represented a critical unmet need in oncology. This new strategy directly confronts this challenge, aiming to create a therapeutic window that was previously considered too narrow or nonexistent.
The foundational idea for circumventing this persistent problem originated from the insightful work of Dr. Miriam Y. Kim, MD. Now an assistant professor of medicine at WashU Medicine, Dr. Kim initiated this pivotal research as a postdoctoral researcher at the University of Pennsylvania, meticulously developing the conceptual framework before continuing her investigations in Dr. DiPersio’s lab. Her dedication ultimately led her to become an independent investigator within the WashU Medicine Division of Oncology, where she also treats patients at Siteman Cancer Center and contributes as a research member. Her pioneering vision laid the groundwork for the clinical translation now being reported.
Precision Gene Editing: Removing CD33 to Shield Healthy Cells
At the heart of this innovative approach is the precise genetic modification of donor stem cells to remove a specific surface protein known as CD33. CD33 is a transmembrane glycoprotein found on the surface of hematopoietic stem and progenitor cells, as well as myeloid lineage cells. While its exact physiological function is not fully understood, it is widely expressed on AML blast cells and is therefore a compelling target for immunotherapy. The objective of this genetic deletion is to engineer healthy blood cells that are no longer vulnerable to therapeutic agents designed to attack CD33, thereby creating a population of "stealth" healthy cells.
The rationale for targeting CD33 is compelling for several reasons. The protein is found exclusively on blood-forming cells and not on other vital tissues throughout the body, minimizing the risk of systemic off-target effects. Furthermore, scientific evidence suggests that CD33 is not essential for normal blood stem cell function; individuals born with natural deficiencies or complete absence of the protein do not appear to suffer from related significant health problems. This biological observation provided a crucial safety margin for the gene editing strategy, indicating that its removal from healthy cells would likely not compromise their normal physiological role.
In the clinical trial, patients with AML and MDS received donor stem cells that had undergone meticulous genetic modification using CRISPR gene editing technology to excise the CD33 gene. This cutting-edge molecular tool allows for highly precise and efficient alterations to the genome. The resulting CD33-deleted stem cell product has been named tremtelectogene empogeditemcel, or "trem-cel" for short. This novel therapeutic candidate was developed by Vor Biopharma, a biotechnology company that also funded the groundbreaking study, highlighting the critical role of industry collaboration in advancing such complex medical innovations.
The underlying theory is elegant in its simplicity and profound in its implications: after a successful transplant with these CD33-deleted stem cells, any cells subsequently found to be carrying the CD33 protein should primarily be residual or relapsed cancer cells. This creates a unique therapeutic window. A subsequent CAR-T therapy or another immunotherapy specifically engineered to target CD33 could then be administered, selectively identifying and destroying those CD33-positive cancer cells while leaving the healthy, newly established donor-derived blood cells completely unharmed. This selective targeting promises to dramatically enhance efficacy while simultaneously mitigating the severe toxicities that have plagued previous attempts at CD33-targeted therapies.
Clinical Trial Details and Promising Early Outcomes
The phase 1/2 multicenter clinical trial enrolled 30 adult patients diagnosed with either AML or MDS, all of whom were considered to be at a high risk of disease relapse following conventional treatment approaches. Before transplantation, the allogeneic (donor) stem cells were meticulously modified using CRISPR gene editing to remove the CD33 gene, producing the trem-cel product.
To rigorously test the hypothesis that these gene-edited stem cells could indeed withstand a therapy directed against CD33, patients in the trial also received a maintenance treatment after transplantation. The chosen drug for this purpose was gemtuzumab ozogamicin (GO). It is important to note that GO is not a CD33-targeted CAR-T therapy; rather, it is an antibody-drug conjugate. This sophisticated therapeutic agent consists of a monoclonal antibody specifically designed to recognize and bind to the CD33 protein, linked to a potent anti-cancer chemotherapy drug. Upon binding to CD33-positive cells, GO is internalized, delivering its cytotoxic payload directly to the cell, thereby inducing cell death.
Gemtuzumab ozogamicin holds FDA approval for certain forms of CD33-positive AML and is currently being investigated in clinical trials for CD33-positive MDS. While it can be effective in preventing relapse, its clinical utility has historically been constrained by significant side effects, most notably liver toxicity (veno-occlusive disease) and severe damage to healthy blood cells, leading to dangerously low levels of white blood cells (neutropenia), red blood cells (anemia), and platelets (thrombocytopenia). The ability of the gene-edited stem cells to protect patients from these severe hematological toxicities was a key endpoint of the study.
The initial results from the trial demonstrated remarkable success in terms of engraftment. All 30 patients achieved successful engraftment by day 28 post-transplant, a crucial milestone indicating that the transplanted stem cells had successfully homed to the bone marrow and commenced the vital process of producing new, healthy blood cells. In fact, some patients reached this milestone even sooner, with platelet production returning by day 16 on average. These recovery times were observed to be strikingly similar to those typically seen with standard, unmodified stem cell transplantation, alleviating concerns that the gene editing process might impede the engraftment or reconstitution capabilities of the donor cells. This finding underscored the safety and feasibility of the trem-cel product.
The average overall survival observed in this high-risk patient cohort was just over 14 months. Within the study protocol, 19 of the enrolled patients received at least one cycle of gemtuzumab ozogamicin as part of a carefully managed dose-escalation protocol, allowing researchers to identify a recommended dose for future studies. Crucially, across the various doses administered, patients consistently maintained their blood cell counts. This observation is profoundly significant: it strongly suggests that the gene-edited transplant effectively protected them from the severe and often dose-limiting drops in blood cells that are commonly encountered when gemtuzumab ozogamicin is used as a maintenance therapy after a conventional, unmodified stem cell transplant. This protective effect directly validates the core premise of the CD33 deletion strategy, demonstrating its potential to allow for more aggressive and sustained CD33-targeted therapy.
Safety Profile and Expert Commentary
The side effects observed during the trial were broadly consistent with those typically associated with standard stem cell transplantation. These included common complications such as anemia, low platelet counts, fever, various infections, and graft-versus-host disease (GVHD), a serious condition in which the donor immune cells perceive the patient’s healthy tissues as foreign and mount an attack. Seven patients regrettably died during the course of the study. Four of these deaths were attributed to the relentless progression of their underlying cancer, underscoring the aggressive nature of AML and MDS in this high-risk population. The remaining three deaths were linked to transplant-related complications, specifically kidney failure, liver toxicity, and sepsis, which are known risks of intensive conditioning regimens and transplantation procedures.
Despite these challenges inherent to treating such advanced diseases, Dr. DiPersio expressed clear optimism regarding the implications of the findings. "We are encouraged by the results of this study showing that a CD33-deleted stem cell transplant looks very similar to the outcomes of standard stem cell transplantation," he stated. Dr. DiPersio, who also directs WashU Medicine’s Center for Gene and Cellular Immunotherapy, emphasized the future potential: "In the future, we are hopeful we will be able to combine this with CD33-targeted immunotherapies, such as CAR-T cells, and improve treatment options for patients with these very aggressive blood cancers." This statement encapsulates the ultimate vision for this groundbreaking technology.
A Glimpse into the Future: Proof-of-Concept with CAR-T Therapy
Beyond the published Nature Medicine study, Dr. DiPersio and his collaborators have also recently reported a compelling single case involving a patient with particularly high-risk AML. This case, detailed in a study published in October 2025 in JCO Precision Oncology, provides a crucial real-world demonstration of the full potential of this combined strategy.
The patient initially received a CD33-deleted stem cell transplant. When the aggressive cancer subsequently returned, a scenario all too common in AML, clinicians were able to deploy a CD33-targeted CAR-T cell therapy. Critically, these CAR-T cells were engineered from T cells provided by the same donor who supplied the original gene-edited stem cells. This innovative sequential approach allowed the CAR-T cells to specifically target the relapsed CD33-positive cancer cells without fear of destroying the patient’s healthy, CD33-negative donor-derived blood system.
The outcome was nothing short of remarkable. The patient, battling one of the most aggressive forms of AML, achieved complete remission and, at the time of reporting, remained cancer-free for more than one year following the CAR-T treatment. Furthermore, normal blood cell production fully returned, and critically, all of the patient’s blood cells were found to lack CD33. This definitive finding provided robust evidence that the genetically engineered donor cells had not only successfully established themselves in the bone marrow but were also functioning perfectly, demonstrating their ability to reconstitute a healthy, CD33-negative hematopoietic system. This single case serves as a powerful proof-of-concept, illustrating the profound therapeutic potential when CD33-deleted transplantation is synergistically combined with CD33-targeted immunotherapies.
Broader Implications and the Dawn of "Immuno-Evasion" Strategies
The success of the trem-cel platform heralds a new era in the treatment of aggressive blood cancers and potentially beyond. This innovative "immuno-evasion" strategy – where healthy cells are genetically engineered to evade attack by targeted immunotherapies – represents a significant paradigm shift in oncology. It moves beyond simply trying to kill cancer cells more effectively, towards a more sophisticated approach that simultaneously protects vital healthy tissues, thereby expanding the therapeutic window for potent, previously constrained treatments.
The implications are far-reaching. For patients with AML and MDS, who currently face grim prognoses upon relapse, this approach offers a renewed sense of hope. It could transform CAR-T cell therapy from a restricted treatment to a viable and potent option for these diseases, potentially leading to higher cure rates and improved quality of life by reducing debilitating side effects. The ability to administer more aggressive, targeted therapies post-transplant without causing severe myelosuppression is a game-changer.
Furthermore, this pioneering work opens doors for similar strategies targeting other antigens shared between cancer cells and healthy tissues. The success with CD33 provides a robust blueprint for future research into other difficult-to-treat cancers where "on-target, off-tumor" toxicity has been a limiting factor. Researchers may now explore deleting other specific proteins from healthy cells to enable targeted attacks on corresponding cancer cells across a broader spectrum of malignancies.
The development of trem-cel and its successful initial clinical validation also underscores the accelerating pace of innovation in gene editing and cellular immunotherapy. While complex and costly, these technologies are rapidly maturing, moving from experimental concepts to tangible clinical solutions. The collaboration between academic institutions like Washington University School of Medicine and industry partners like Vor Biopharma is crucial for translating such cutting-edge science into patient benefit.
However, challenges remain. Larger, randomized Phase 3 clinical trials will be necessary to definitively confirm the efficacy and long-term safety of the trem-cel approach in combination with CD33-targeted CAR-T therapies. Manufacturing complexities, the high cost of gene editing and CAR-T treatments, and ensuring equitable access for
